# A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

> **NCT03093116** · PHASE1,PHASE2 · RECRUITING · sponsor: **Turning Point Therapeutics, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Locally Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** Oral repotrectinib (TPX-0005)

## Key facts

- **NCT ID:** NCT03093116
- **Lead sponsor:** Turning Point Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-07
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-02-29
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093116

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093116, "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03093116. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*